Blood and spinal fluid profiling in Alzheimer’s disease appears to track brain pathology in a strict sequence, tying circulating and cerebrospinal measurements to amyloid and neurodegeneration timing. Published as an observational study, the report links how biomarkers evolve with the appearance and progression of hallmark brain plaques. The work reinforces the clinical relevance of longitudinal sampling—suggesting clinicians may better interpret diagnostic trajectories when placing fluid markers into a staged biological order. For researchers, the study provides a framework for aligning biomarker staging with imaging and clinical endpoints, potentially improving trial enrichment and outcome interpretation. The key question going forward is whether the same staged progression holds across broader demographic and comorbidity strata and how well it predicts conversion rates in preclinical populations.